Seer Competitors

AbCellera Biologics (NASDAQ:ABCL) and Seer (NASDAQ:SEER) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares AbCellera Biologics and Seer's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares AbCellera Biologics and Seer's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings for AbCellera Biologics and Seer, as provided by MarketBeat.com.

AbCellera Biologics presently has a consensus target price of $52.80, indicating a potential upside of 86.90%. Seer has a consensus target price of $68.00, indicating a potential upside of 26.25%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Seer.

Summary

AbCellera Biologics beats Seer on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Seer and Sana Biotechnology, as provided by MarketBeat.com.

Seer presently has a consensus price target of $68.00, indicating a potential upside of 26.25%. Sana Biotechnology has a consensus price target of $40.00, indicating a potential upside of 59.74%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Seer.

Profitability

This table compares Seer and Sana Biotechnology's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Seer and Sana Biotechnology's gross revenue, earnings per share and valuation.

Summary

Sana Biotechnology beats Seer on 1 of the 1 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares Seer and Abcam's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Seer and Abcam, as reported by MarketBeat.

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 26.25%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 12.47%. Given Seer's stronger consensus rating and higher possible upside, research analysts plainly believe Seer is more favorable than Abcam.

Profitability

This table compares Seer and Abcam's net margins, return on equity and return on assets.

Summary

Seer beats Abcam on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Profitability

This table compares Seer and Nuvation Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Seer and Nuvation Bio, as provided by MarketBeat.com.

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.52%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Seer.

Earnings and Valuation

This table compares Seer and Nuvation Bio's gross revenue, earnings per share (EPS) and valuation.

Summary

Nuvation Bio beats Seer on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Seer and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations for Seer and ImmunityBio, as provided by MarketBeat.

Seer currently has a consensus price target of $68.00, indicating a potential upside of 26.25%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 38.35%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Seer.

Profitability

This table compares Seer and ImmunityBio's net margins, return on equity and return on assets.

Summary

ImmunityBio beats Seer on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares Seer and Immunocore's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Seer and Immunocore's gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Seer and Immunocore, as provided by MarketBeat.

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 37.55%. Given Immunocore's stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Seer.

Summary

Immunocore beats Seer on 2 of the 2 factors compared between the two stocks.